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Abstract: The prognostic characteristics of pancreatic cancer (PC) are determined by the contributing factors from the tumor
microenvironment. Leptin is a critical oncogenic factor released by adipocytes as an adipokine into the tumor microenvironment,
where it promotes tumor development by activating cancer stem cell (CSC) molecular regulators Notch, Hedgehog, and Wnt/β-catenin
signaling. One of the downstream targets of these pathways is CDK4/6 and cyclin D which is controlled by P16 INK4A that is highly
mutated in PC. Therefore, the purpose of this study was to determine the effect of a CDK4/6 inhibitor, palbociclib, on Leptin-induced
PC cells and to target the Notch, Hedgehog, and Wnt/β-catenin signaling pathways via miR-150, miR-506, and miR-208 modulation.
Leptin treatment increased the ability of Panc-1, MiaPaCa-2, and Capan-2 cells to proliferate and decreased the effect of palbociclib.
Additionally, tumorspheres were generated from Leptin-treated (Leptin+) and Leptin-untreated (Leptin-) Panc-1 and MiaPaCa-2 cells
and transfected with miR-506, miR-150 (tumorsuppressor miRNAs), or anti-miR-208 (oncomiR), followed by palbociclib treatment.
Forced expression of miR-506 or miR-150 significantly increased the susceptibility of Leptin+ cells to palbociclib treatment by inhibiting
colony and tumor spheroid formation, and CD44 expression in Panc-1 and MiaPaCa-2 cells. Additionally, the increased miR-150
expression is more effective at inhibiting N-cadherin, β-catenin, p-GSK3β, Notch, and Wnt5a/b expression in Leptin-/+ Panc-1 and
MiaPaCa-2 cells. As a result, palbociclib suppressed the CSC profile induced by leptin treatment, inhibiting both tumorsphere forms and
leptin-targeted signaling pathways, thereby disabling the Panc-1 and MiaPaCa-2 cells’ resistance mechanism. Increased expression of
miR-506 or miR-150 and inhibition of miR-208 enhanced sensitivity of Panc-1 and MiaPaCa-2 Leptin-/+ cells to palbociclib treatment.
As a result, this study proved that combining inhibitors of CSC molecular regulators with palbociclib improves the success rate of
inhibition of PC cell proliferation.
Key words: Pancreatic cancer, CDK4/6 inhibitor, miR-506, miR-150, miR-208, Wnt/ β-catenin, leptin

1. Introduction
Pancreatic cancer, which has almost the same incidence
and mortality rate and a 5-year survival rate of only 6.5%,
is an aggressive type of cancer that cannot be diagnosed
early (Kim et al., 2014). Although most PC risk factors such
as obesity do not directly cause PC, they trigger cancer
development. The mortality rate due to PC is more than
50% in obese individuals with a body mass index (BMI)
higher than 30. Various hormones released from adipose
tissue due to obesity and inflammatory cytokines such
as adipokines trigger obesity-related cancer (Sakorafas
et al., 2000). Leptin, an adipokine, is an essential factor
that increases tumor cell proliferation and angiogenesis
in cancer cases (Pothuraju et al., 2018). Accordingly,
increased leptin triggers cancer formation by increasing
insulin growth factor (IGF-1) and increasing cell growth
through activation of PI3K/AKT/mTOR signaling and

suppressing apoptosis (Harbuzariu et al., 2018; Pothuraju
et al., 2018). A study examining the expression level of
leptin, which causes increased breast cancer development
showed that it accelerates the PC process by activating the
Notch signaling pathway associated with tumor metastasis
and CSC differentiation in BxPC-3, MiaPaCa-2, Panc-1
and AsPC-1 PC cells (Ramakrishnan et al., 2011).
Accordingly, adipokine levels and their induced
signaling pathways such as Notch, Hedgehog or Wnt/βcatenin are essential therapeutic targets in the diagnosis
and treatment of PC. Abnormal activation of these
signaling pathways is observed in many cancer cases
because the induction of drug resistance mechanisms
and metastasis process, especially by triggering CSC
differentiation (Nusse and Clevers, 2017), (Matsui,
2016). Therefore, targeting these signaling pathways in
suppressing tumor growth is a therapeutic target that
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will prevent drug resistance mechanisms, metastasis, and
cell proliferation signals; moreover, it will yield valuable
results for clinical trials. Pancreatic CSCs are one of the
most important factors hindering the PC therapy process.
CD133/CXCR4, PD2/Paf1, CD44/CD24/ ESA, c-MET, and
ALDH1 are pancreatic CSC markers and their expression
levels are quite high in drug-resistant cell populations.
The drug combinations of cyclopamine, rapamycin, and
gemcitabine reduced cell survival through targeting CSCs
(Chen et al., 2013).
An important reason why the incidence of PC and the
death rate due to PC are very close to each other is because
PCs are generally metastatic tumors. According to studies,
pancreatic CSCs and epithelial-mesenchymal transition
(EMT) are interrelated with leptin that is an important
factor in the tumor microenvironment that accelerates
tumor development by triggering CSC molecular
regulators, Notch, Hedgehog, Wnt/β-catenin (Harbuzariu
et al., 2018). The target of these signaling pathways, cyclin
D1, is expressed at high levels in PC cells (Vaz et al.,
2014). Therefore, it is predicted that an inhibitor targeting
cyclin D1 may be helpful in the treatment of aggressive
PC. Palbociclib, a CDK4/6 inhibitor, is approved by the
FDA and used in advanced postmenopausal breast cancer
therapy. In PC cases, cell proliferation due to high cyclin
E1 can be suppressed by the CDK4/6 inhibitor palbociclib
(Franco et al., 2014). Recent studies have shown that
microRNAs (miRNAs) play a role in cell proliferation,
stem cell differentiation, adipogenesis and metastasis by
regulating stem cell markers such as c-Met and ALDH1
in normal and cancer cells (Guo et al., 2018; Guo, Xu,
et al., 2018) ). According to the information obtained
from miRNA platforms, miR-150 as a tumor suppressor
miRNA, targets β-catenin, which plays vital role in EMT,
and PPARGC1α genes that function in adipose tissue (Li
et al., 2019). Another study showed that miR-506 triggered
autophagy-related death by targeting the STAT3 gene of PC
cells (Zhou et al., 2019). According to the data we obtained
from miRNA platforms, Notch and vimentin are among
the target genes of miR-506 (Arora et al., 2013). Another
study stated that miR-208, an oncomiR, acts as an obesity
trigger in mouse cardiomyocyte cells and its expression
decreases in the presence of mTOR inhibitor rapamycin,
while weight loss increases despite leptin resistance (Gul
et al., 2015).
In this study, CSC phenotype of Panc-1 and MiaPaCa-2
PC cells were induced by leptin treatment which increased
the colony forming potential by 50% and these cells
expressed the Notch and the mesenchymal markers such
as CD44, N-cadherin, Vimentin higher than control
cells. A unique value of our study is to investigate the
effect of palbociclib on these cells and targeting Notch,
Hedgehog and Wnt/β-catenin signaling pathways through
modulation of miR-150, miR-506 and miR-208. According

to the results obtained, palbociclib suppressed the CSC
features and cell proliferation due to increased level of
miR-506 or miR-150 in leptin-/+ Panc-1 and MiaPaCa-2
cells.
2. Materials and methods
2.1. Cell culture
MiaPaCa-2 (ATCC® CRL-1420TM, RRID: CVCL_0428),
Panc-1 (ATCC® CRL1469TM, RRID: CVCL_0480) and
Capan-2 (ATCC® HTB-80™, RRID: CVCL_0026) pancreatic
cancer cell lines were incubated in Dulbecco’s modified
Eagles medium (GIBCO-Life Technologies, Carlsbad,
CA, USA) with 10% fetal bovine serum (FBS) (Pan
Biotech GmbH, Aidenbach, Germany) and 1% penicillin/
streptomycin (Pan Biotech GmbH, Aidenbach, Germany)
in 37 °C with 5% CO2. Leptin treatment was carried out
in such a way that 1.2 nM (40 ng/mL) recombinant leptin
(level in PC patient serums) (Peprotech Cat. No: 300-27,
Hamburg, Germany) was incubated for 24 h after 16-h
serum starvation (without FBS) of PC cells (Ekmen et al.,
2016) and cells were continuously treated with the certain
dose of leptin (Fan et al., 2015). These cells were named as
leptin+ cells. Transfection of miR-506 or miR-150 mimic
and anti-miR-208 was proceeded as described previously
(Rencuzogulları et al., 2021). Briefly, Panc-1, MiaPaCa-2,
and Capan-2 PC cells with/without leptin were transfected
with a 1:3 lipogenic transfection agent, miRNA mimic
5 nM (miRCURY LNA miRNA Mimics, Cat. No:
339173; Qiagen, Hilden, Germany) and anti-miR 50 nM
(miRCURY LNA miRNA Inhibitors, Cat. No: 339121;
Qiagen, Hilden, Germany). mirVana™ miRNA Mimic,
Negative Control (Cat. No: 4464058; Thermo Scientific,
Massachusetts, USA), and Anti-miR™ miRNA Inhibitor
Negative Control (Cat. No: AM17010 Thermo Scientific,
Massachusetts, USA), which had no identifiable effects on
known miRNA function, were used to control transfection
quality and evaluation of experimental miRNA mimic/
anti-miR on target gene expression. After the transfection
agent was kept in medium without FBS for 5 min (min)
at room temperature, it was combined with the medium
containing mimic or anti-miR and incubated for 25 min at
room temperature. Cells were incubated with transfection
solution for 48 h.
2.2. MTT cell viability assay
1x 104 leptin- and leptin+ PC cells were seeded into 96well plates. Following overnight incubation time, the cells
were exposed to 2 and 3 µM palbociclib (10 mM main
stock, Selleckhem, Houston, USA) for 24 h. Then 10 µL
of 2,5-diphenyl-2H-tetrazolium bromide (MTT) reagent
(5 mg/mL) was added to each well and incubated for 4 h
at 37 °C with 5% CO2. Formazan crystals were dissolved
with 100 µL of DMSO and analyzed with an Elisa reader
at 570 nm. MTT assay was performed at least three times
with four repeats.
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2.3. Colony formation assay
Leptin treatment was performed as previously mentioned
as 1.2 nM leptin for 24 h following 16 h serumstarvation. At that point, miRNA mimic and anti-miRNA
transfections were proceeded for leptin+ and leptin- cells.
The cells were seeded into 6-well plate at 3 x 103 cells/well
and then they were exposed to 3 µM palbociclib treatment.
Colony assay was then performed as described previously
(Rencuzogulları et al., 2020). Briefly, drug containing
media was removed over the cells and fresh media was
added. Then, the cells were incubated until untreated
control group reached 80% confluence of well following
treatments. Following fixation, the cells were stained with
0.5% crystal violet. Colonies were visualized and counted
by ImageJ analysis program.
2.4. miRNA analysis
5x105 cells were seeded into 6-well plates. Following
overnight incubation time, the cells were transfected
with miR-506, miR-150, and anti-miR-208 for 48 h, as
mentioned in part 2.1. Then the cells were treated with 3
µM Palbociclib for 24 h. According to the manufacturer’s
instructions, total miRNA was extracted by using miRNeasy
(Qiagen). The cDNA amplification was proceeded by
miScript RT kit (Qiagen). The accuracy of transfection
of mimic miR-506 or miR-150 and anti-miR-208 was
controlled by measuring the expression of mature miRNAs
with quantitative real-time PCR (qRT-PCR) with miScript
SYBR Green PCR Kit (Qiagen). The human noncoding
small nuclear RNA U6 was used as the endogenous control
to normalize the obtained miRNAs. The primers for
qRT-PCR: miR-506 5’- CCTTGGCACCCTTCTGTAGA
-3’; miR-150: 5’-GAGAGACGCATAAAAGCCGC-3’;
miR-208:
5′-ATAAGACGAGCAAAAAGCTTGT-3′
U6-F:
5’-TGGCACCCAGCACAATGAA-3’;
U6-R:
5’-CTAAGTCATAGTCCGCCTAGAAGCA-3’.
The
amplification reactions were performed in triplicate
using the following cycle: 10 min at 95 °C, followed by 40
cycles of 15 s at 95 °C and 1 min at 60 °C. The Cq values
were calculated using the Bio-Rad CFX Manager System
software. The relative fold change for each miRNA was
calculated using the comparative Cq (2−ΔΔCq) method.
2.5. Annexin V/PI staining and cell cycle analysis
Apoptotic cells were examined after cells were stained by
Annexin V and propidium iodide (PI), by flow cytometer
analysis using C6 software (BD Bioscience). Following
treatments of Panc-1 and MiaPaCa-2 cells were harvested
by trypsin‐EDTA. 104 cells were gated and analyzed with
FL1(488 nm) and FL3 (640 nm) filters. Cell cycle analysis
was performed by PI staining after cells were fixed with
70% Ethanol. Flow cytometric analysis was continued for
104 cells with FL3 filter (BD Accuri).
2.6. Immunofluorescence analysis
Immunofluorescence analysis was performed to confirm
the CD44 level by florescence microscopy. Panc-1 and
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MiaPaCa-2 cells transfected with miR-506 mimic, miR150 mimic, and anti-miR-208 were seeded at 5x104 cells
on a coverslip and allowed to adhere overnight. After 24
h of applying 3 µM palbociclib, the medium on the cell
was gently removed. After washing with 1X PBS, the
cells were fixed at room temperature for 20 min with
methanol/acetone (1:1) fixative at –20°C. 3% BSA was
used as the blocking solution to prevent nonspecific
binding. Next, the cells were incubated with CD44
primary antibody (prepared 1:1000 with 3% BSA) at
room temperature for 2 h and then they were washed 3
times with 1X PBS containing 0.01% Triton-x to eliminate
excess binding. It was incubated with an Alexa-488conjugated antimouse antibody as secondary antibody for
2 h at room temperature. The cells were observed under a
fluorescence microscope. The total fluorescence integrity
was quantitatively calculated and analyzed by the Image J
method calculated by the formula that corrected total cell
fluorescence = integrated density – (area of selected cell ×
mean fluorescence of background readings.
2.7. Wound healing assay
The effect of palbociclib on cell migration in MiaPaCa-2
and Capan-2 PC cells was investigated with wound healing
test, which is a simple and inexpensive method. When
PC cells and cells transfected with miR-506 mimic, miR150 mimic, and anti-miR-208 reached 80% density, 3 µM
palbociclib was applied and then the cells were incubated
in medium containing 1% FBS overnight. The 6-well plate
with the cells was drawn with the 10 µm tip. The cells were
washed with 1X PBS and then incubated with treated and
nontreated media. However, the media used in this assay
contained %5 FBS in order to facilitate cell migration.
Wound area was visualized at 0 and 48 h with a light
microscope and with DiOC6 staining and the migration
values of cells were calculated by taking the average values
of the images recorded from 5 different regions.
2.8. Soft agar assay
The effect of Panc-1 and MiaPaCa-2 cells that acquired
CSC profile by leptin application on the 3D tumorsphere
structure of palbociclib after miRNA mimic, and antimiR transfection was analyzed. Firstly, miR-506 mimic (5
nM), miR-150 mimic (5 nM) and anti-miR-208 (50 nM)
were transfected to leptin-/+ Panc-1 and MiaPaCa-2 cells
for 48 h and grown in soft agar for 14 days at 37 °C. To
form the ground layer, soft agar consists of two layers.
0.5% agarose, 20% FBS, and 2% Pen./Strep. It was mixed
with 2X DMEM containing 1:1 ratio. The 6-well plate was
homogeneously coated with 1 mL of basement solution.
The upper gel solution containing 0.3% agarose and 2X
DMEM containing 2.5x104 cells/mL is prepared at a ratio
of 1:1, and 3 µM palbociclib was added to the top layer
solution at this stage. In order to prevent the agarose gel
from drying, 500 µL of medium with or without drug was
added to the top. Colony diameters were examined at the
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end of the 14th day. Colony diameters were compared
between leptin-treated and non-leptin-treated cells, and
statistical analysis was performed.
2.9. CD44, CD144, and CD24 analysis
Leptin- and leptin+ PC cells were seeded at 6x105 cells/well
then transfected with miR-506 mimic, miR-150 mimic,
and anti-miR-208 for 48 h and then 3 μM palbociclib was
applied for 24 h. The cells were blocked with 1% BSA for
30 min at room temperature. They were then washed with
1X PBS containing 0.01% triton-x and then incubated at
room temperature for 1 h with fluorescent monoclonal
antibodies for CSC markers (CD24+, CD44+, CD133+
conjugated with PE, APC, and FITC, respectively)
prepared at 1:1000 in BSA. Cells incubated with primary
antibodies and unstained control groups were analyzed
for 104 cells by cell flow cytometry (BD Bioscience). The
cells stained with CD44 only were determined on the dot
plot with the SSC and FL-1 (488 nm) filter. The drug-free
control and other cell groups could be compared and
analyzed according to this limit. Boundaries were set with
SSC with FL-2 (565 nm) filter for CD133 and with SSC
with FL-3 (640 nm) filter for CD24.
2.10. Immunoblotting
Total protein isolation was performed from leptin- and
leptin+ Panc-1 and MiaPaCa-2 ceflls after miR-506 mimic
and miR-150 mimic transfections and 3 µM palbociclib
treatment as described previously (Berrak et al., 2016).
Primary antibodies were used as 1:1000 dilution and
secondary antibodies were used with 1:3000 dilution.
N-cadherin, β-Catenin, p-GSK-3β (S9), Dvl-2 Wnt5a/b,
Notch-1, and CD44 protein expressions were investigated
in Panc-1 and leptin+ Panc-1 cells. Protein expressions of
p-AKT (S473), E-cadherin, β-Catenin, Vimentin, Dvl-2,
Notch-1, and Snail in MiaPaCa-2 and leptin+ MiaPaCa-2
cells were investigated. It was analyzed by normalizing
according to β-actin levels with the Image J program.
2.11. Statistical analysis
GraphPad software (4.04 version) was used for the
analysis of at least 2 replications of the experiment
(RRID:SCR_000306). MTT cell viability, colony
formation analysis, wound healing assay, soft agar assay,
and flow cytometric analysis was proceeded by three
biological repeats. The results were statistically analyzed
by Bonferroni’s multiple comparison analysis method.
Immunoblotting results were calculated numerically with
the Image J (RRID:SCR_003070) analysis program and
statistical data were obtained with 2-way ANOVA Tukey’s
multiple comparison analysis by normalizing each band
profile according to its β-actin values.
2.12. List of antibodies
Primary antibodies N-cadherin, E-cadherin, Vimentin,
β-catenin, p-GSK3β (S9), Dvl-2, Wnt5a/b, Notch1, CD44,
p-Akt (ser473), Snail, and actin were purchased from Cell

Signaling Technology (CST; Danvers, MA). CD44, CD133,
and CD24 antibodies were purchased from Biolegend
(BioLegend, Inc., San Diego, USA). Secondary Alexa 488‐
conjugated antibody and HRP conjugated antibody were
purchased from CST.
3. Results
3.1. Palbociclib suppressed the colony forming potential
of Panc-1 and MiaPaCa-2 cells, which increased with
leptin treatment
It was determined that the cell proliferation rate of Panc1 and MiaPaCa-2 cells treated with leptin increased and
accordingly, it caused an increase in the relative cell
viability by 25% and 33%, respectively. The viability of
Panc-1 and Panc-1 Leptin+ cells were 76% and 101% after
treatment with 2 µM palbociclib, respectively, whereas it
was 69% and 85% following 3 µM palbociclib treatment,
respectively (Figure 1A). The viability of MiaPaCa-2 and
MiaPaCa-2 Leptin+ cells treated with 2 µM palbociclib
was 68% and 110%, whereas it was 55% and 80% following
3 µM palbociclib treatment, respectively (Figure 1B). As
a result, it was determined that 3 µM palbociclib caused
a significant decrease in the viability of the cells with
or without leptin treatment. As a result of the colony
formation experiment, 20× magnified images obtained
by a light microscope of cells stained with crystal violet
were shown (Figure 1C). By leptin application, the
diameters of Leptin+ Panc-1, MiaPaCa-2, and Capan-2
cell colonies expanded. Another significant issue is that
Panc-1 and MiaPaCa-2 cell morphologies were changed
by leptin application. Accordingly, the cells shrunk and
had prominent fibroblast-like extensions. Colony-forming
potential of leptin+ cells was significantly suppressed by
the treatment of 3 µM palbociclib. Leptin treatment was
repeated every 4 days and light microscopy images were
taken at ten-fold magnification of Panc-1 and MiaPaCa-2
cells, which reached 90% confluence. According to the
results obtained, cell clusters like stem cell spheroid
structures (Vazquez et al., 2017) were observed in the
leptin-administered groups (Figure 1D).
3.2. Palbociclib modulated the intracellular level of miR506, miR-150, and miR-208 in leptin-/+ Panc-1 and
MiaPaCa-2 cells
To understand the regulatory role of palbociclib on miRNA
expression, under leptin-mediated responses in Panc-1 and
MiaPaCa-2 cells, miR-506 and miR-150 mimic miRNAs
and anti-miR-208 were transfected. Moreover, negative
controls (NC) which had no identifiable effects on known
miRNA function were used to control transfection quality
and evaluation of experimental miRNA mimic/anti-miR
on target gene expression. In this study, the expression
levels of the indicated miRNAs in leptin-treated cells were
also normalized according to the intracellular endogenous
control miRNA, RNU6 (Figure 2). The miR-506 level
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Figure 1. Leptin reduced the sensitivity of pancreatic cancer cells to palbociclib (PD) treatment. A-B. 40 ng/mL leptin was applied to Panc-1 (A) and MiaPaCa-2 (B) cells. MTT cell
viability test was performed after 24 h of 3 µM palbociclib treatment. Four replicates of 2 different experiments mean/SD analysis was proceeded. C. The long-term effect of PD on
leptin treated (leptin+) and un-treated (leptin -) Panc-1, MiaPaCa-2 and Capan-2 cells was analyzed by colony formation assay. D. Representation of cell clusters in leptin-treated
cells. When leptin-treated Panc-1 and MiaPaCa-2 cells reached approximately 90% density. 10× magnification. Scale bar is 100 µm.
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decreased 1.6-fold (p < 0.05) in leptin-treated Panc-1 cells
compared to the control group and increased when 3 µM
palbociclib was treated. After miR-506 mimic transfection,
miR-506 level increased 4- and 3.6-fold in Panc-1 and
Panc-1 leptin+ cells, respectively, whereas miR-506
expression increased 5.7- and 4.8-fold, respectively, with
palbociclib treatments (****p < 0.0001) (Figure 2A). We
determined that miR-506 level was lower in MiaPaCa-2
cells than in Panc-1 cells. When leptin was treated,
this level decreased approximately 2 times (p < 0.05).
Palbociclib treatment did not significantly differ in miR506 level in leptin+ MiaPaCa-2 cells. However, palbociclib
treatment increased miR-506 expression 10-fold (****p <
0.0001) in miR-506 mimic transfected cells, while there
was no difference observed in leptin+ cells (Figure 2B).
miR-150 expression, which was expressed in low amounts
in Panc-1 cells, was further decreased by leptin treatment.
miR-150 mimic transfection increased 10 times (****p
< 0.0001) in Panc-1 cells and 1.5 times (*p < 0.05) in
Panc-1 leptin+ cells compared to the control group. With
Palbociclib treatment, 16-fold and 4-fold increase was
observed in miR-150 mimic transfected Panc-1 and Panc1 leptin+ cells compared to the control group, respectively
(p < 0.0001) (Figure 2C). miR-150 expression was found
to be 3 times lower in leptin-treated cells compared to the
control group. MiR-150 expression increased 3.2-fold and
3-fold, respectively, in MiaPaCa-2 and MiaPaCa-2 leptin+
cells with miR-150 transfection. Palbociclib treatment
increased miR-150 expression by 3.6-fold compared to the
control group in miR-150 mimic-transfected MiaPaCa-2
cells; however, no significant difference was observed in
leptin+ cells (Figure 2D). Leptin caused an increase in
miR-208 level. With Palbociclib application, miR-208 level
decreased 4-fold, but this decrease was only 1.3-fold in
leptin+ cells. With anti-miR-208 transfection, miR-208
expression was significantly reduced in Panc-1 leptin-/+
cells. A higher suppression of miR-208 expression was
observed when palbociclib was applied to the same cells
(****p < 0.0001). However, it was noted that miR-208
expression was 1.5 times higher when leptin+ Panc-1 cells
were compared with leptin- Panc-1 cells (Figure 2E). miR208 expression increased 2.1-fold with leptin treatment to
MiaPaCa-2 cells, as in Panc-1 cells **p < 0.02). However,
palbociclib caused a 3-fold (***p < 0.001) and 2-fold (**p
< 0.02) increase in miR-208 expression in MiaPaCa-2 and
leptin+ cells compared to the control group, respectively.
Anti-miR-208 caused a significant decrease of miR-208
levels in leptin+/- MiaPaCa-2 cells (Figure 2F).
3.3. Modulation of miR-506, miR-150, and miR-208
levels affected the apoptotic response of Panc-1 and
MiaPaCa-2 cells to Palbociclib treatment
The effects of miR-506, miR150 mimic and anti-miR-208
transfections in Panc-1 and MiaPaCa-2 cells on the
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apoptotic cell death of palbociclib were examined by cell
flow cytometry with AnnexinV/PI staining (Figures 3A–
3D). Apoptotic cell death was increased after palbociclib
treatment to 17% in miR-506 transfected-Panc-1 cells and
to %15 in miR-150 transfected-Panc-1 cells (Figure 3AB). This ratio was analyzed respectively as 10% and 17%
in MiaPaCa-2 cells (Figures 3C and 3D). Therefore, forced
expression of miR-150 increased sensitivity of Panc-1 and
MiaPaCa-2 cells to palbociclib treatment. Moreover, the
downregulation of miR-208 enhanced the apoptotic effect
of palbociclib in both cell lines. The effect of palbociclib on
cell cycle after miRNA transfections was investigated by
flow cytometry after propidium iodide staining in Panc-1
and MiaPaCa-2 cells (Figure S1). No significant difference
was observed in the effect of palbociclib on cell cycle after
miR-506 and miR-150 mimic transfection into Panc-1 and
MiaPaCa-2 cells. When palbociclib was applied to cells
that transfected with miR-506 mimic, an increase of 6%
was observed in the SubG1 population in both Panc-1
and MiaPaCa-2 cells. Suppression of miR-208 increased
cells in G1 phase by 5%. However, when palbociclib was
applied to these cells, it was determined that 58% of the
cells remained in the G2/M phase in Panc-1 cells.
3.4. Upregulation miR-150 caused significant decrease
of migration potential of MiaPaCa-2 cells following
palbociclib treatment
CD44 is a transmembrane cell surface receptor that acts
as a tumor initiating factor which PC has a high level in
stem cell profiles and is an important therapeutic target.
Immunofluorescence technique was used to determine
the effect of palbociclib on CD44 expression in Panc-1
and MiaPaCa-2 cells modulated for miR-506, miR-150
and miR-208 (Figures 4A–4D). CD44 levels displayed as
green fluorescent dots were analyzed quantitatively by
calculating the total fluorescence brightness. The result
was normalized by dividing by the number of cells so that
the decreased cell number with palbociclib and miRNA
treatments did not affect the CD44 expression. CD44
expression was significantly decreased by palbociclib
treatment in Panc-1 (Figures 4A and 4B) and MiaPaCa-2
(Figures 4C and 4D) cells (****p < 0.0001). When
intracellular miR-506 or miR-150 level was increased,
it was determined that CD44 level decreased more with
palbociclib treatment in Panc-1 and MiaPaCa-2 cells (*p
< 0.05). CD44 level showed a significant decrease when
intracellular miR-208 was inhibited in both Panc-1 and
MiaPaCa-2.
Wound healing assay was performed to examine the
effects of miR-506, miR-150 and miR-208 on the migration
potential of palbociclib-treated MiaPaCa-2 (Figures 4E
and 4F) and Capan-2 cells (Figures 4G and 4H). The
results obtained were graphed by taking the average of the
measurements made from five different regions. Compared
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Figure 3. miR-506, miR-150 mimic, and anti-miR-208 transfections increased apoptotic effect of palbociclib in Panc-1 and MiaPaCa-2 cells. A-D. Cells were exposed to 3 µM
palbociclib for 24 h following the transfection protocol. AnnexinV/PI- stained Panc-1 (A-B) and MiaPaCa-2 (C-D) cells were analyzed by flow cytometry. The results obtained are
the mean/SD of two different experiments. NC: Negative control B. **p < 0.01 (3 µM PD-treated vs. miR-506-transfected and antimir-208-transfected), ***p < 0.001 (nontreated
control vs. mimic miR-506 or anti-miR-208-transfected) D. *p < 0.05 (nontreated control vs. 3 µM PD-treated; 3 µM PD-treated vs. anti-miR-208-transfected), **p < 0.01 (nontreated
control vs. anti-miR-208-transfected; nontreated control vs. 3 µM PD-treated-mimic miR-150-transfected), ***p < 0.001 (nontreated control vs. 3 µM PD-treated-mimic miR-506transfected; nontreated control vs. 3 µM PD-treated-anti-miR-208-transfected).
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Figure 4. Increased expression of miR-506 or miR-150 reduced the metastatic potential of pancreatic cancer cells. A-D. Effect of palbociclib on CD44 expression in Panc-1 (A-B)
and MiaPaCa-2 (C-D) cells with increased miR-506, miR-150 expression and inhibited miR-208 expression was determined by immunofluorescence assay. B. CD44 expression
was analyzed with the Image J program by taking the total fluorescent intensity values of the green fluorescence. In order for the decrease in cell numbers not to change CD44
expression, the obtained cell brightness results were obtained by dividing by the number of nuclei (DAPI). *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. E-H. Effect of miR506, miR-150, and miR-208 on the migration potential of palbociclib-treated MiaPaCa-2 (E-F) and Capan-2 (G-H) cells was analyzed by wound healing assay. Wound closure was
visualized by fluorescence microscopy after DiOC6 staining. Data presented is mean ± SD of at least three separate experiments * p < 0.05 (MiaPaCa-2: 3 µM PD treated vs. 3 µM
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with the control group, an increase of intracellular miR506 and miR-150 was observed; however, suppression of
miR-208 decreased the migration potential of MiaPaCa-2
cells. The wound healing suppressive effect of palbociclib
was significantly increased when the intracellular miR150 level was increased, while a decrease in cell viability
was also observed (*p < 0.05). When palbociclib was
applied to miR-208-inhibited MiaPaCa-2 cells, it was also
determined that the migration capacity of the cells was
reduced. However, when miR-208 was inhibited, wound
healing of Capan-2 cells was accelerated and the wound
was closed entirely.
3.5. The colony-forming potential of Panc-1 and
MiaPaCa-2 cells increased by leptin treatment was
suppressed by miR-506 mimic, miR-150 mimic and antimiR-208 transfections
Colony numbers and colony diameters were enlarged in
leptin-treated Panc-1 (Figure 5A) and MiaPaCa-2 (Figure
5B) cells. When the expression of miR-506 or miR-150
was increased in leptin+ Panc-1 and MiaPaCa-2 cells, a
decrease was observed in the number of colonies compared
to both control and leptin+ cells, and a significant decrease
was observed in the number of colonies when palbociclib
was applied to these cells. Anti-miR-208 and palbociclib
treatment synergistically reduced the colony numbers of
leptin+ Panc-1 and MiaPaCa-2 cells. A striking image
is the colony diameter width of the transfected Panc1 leptin+ cells. Compared to the control group, it was
observed that the colony numbers were lower, but the
colony diameters were larger. It was determined that the
increase of miR-506, miR-150 expression, and inhibition
of miR-208 expression significantly suppressed the colony
forming potential of both Panc-1 leptin+ and MiaPaCa-2
leptin+ cells. In addition, changing miRNA expressions
produced a synergistic response with palbociclib, with
colony numbers significantly reduced compared to control
groups. The question arose whether miR-506, miR-150, and
miR-208 would give the same answer when leptin+ cells
form three-dimensional (3D) tumorsphere structures. For
this, soft agar experiment was carried out (Figures 5C–5F).
Tumorsphere structures of Panc-1 (Figures 5C and 5D)
and MiaPaCa-2 (Figures 5E and 5F) cells were significantly
suppressed by the increase of intracellular miR-506 and
miR-150 or by inhibition of miR-208 compared to the
control group. Moreover, the extensive reduction in tumor
diameters with palbociclib was observed. Tumorspheric
structures gained a homogeneous and spherical structure
with leptin treatment; however, when miR-506 and miR150 expressions increased, respectively, tumorigenicities
of Panc-1 and MiaPaCa-2 leptin+ cells were suppressed
and their sphere diameters decreased significantly. This
effect was further increased with palbociclib treatment to
the same cells (****p < 0.0001).
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3.6. Palbociclib and miR-506 or miR-150 mimic
treatment in Panc-1 and MiaPaCa-2 cells decreased
CD44 expression, but CD133 and CD24 CSC membrane
receptors caused different responses in their expression
The effects of miR-506 or miR-150 mimic and palbociclib
treatment which significantly suppress tumorsphere
formation of leptin-/+ Panc-1 (Figures 5D, 5G, and 5H)
and MiaPaCa-2 (Figures 5J–5L) cells, on CD44 (Figures
5G–5J), CD133 (Figures 5H–5K), and CD24 (Figures
5I–5L) membrane receptors were investigated by cell flow
cytometry. CD44 expression was detected over 50% in
both leptin-/+ Panc-1 and MiaPaCa-2 cells. Additionally,
leptin led to significant increase of CD44 levels in Panc1 and MiaPaCa-2 cells. Although this rate decreased
with palbociclib alone, the increase of miR-506 and miR150 expressions in the cell significantly decreased CD44
expression for both cell lines. Increased miR-506 and
miR-150 caused an upregulation in CD133 level in Panc1 and MiaPaCa-2 cells. This rate is 30% and 35% less in
miR-506 and miR-150 mimic transfected Panc-1 leptin+
cells, respectively (**p < 0.02). Although palbociclib did
not affect CD133 level in Panc-1 cells, CD133 levels was
decreased in miR-506 and mimic-transfected Panc-1
leptin+ cells by 20% and 15%, respectively, compared to
the control group (**p < 0.02). It was determined that
there was a 22% increase in CD133 level with leptin in
MiaPaCa-2 cells. However, CD133 level in MiaPaCa-2
leptin-/+ cells decreased by 10% with palbociclib. In
MiaPaCa-2 cells transfected with miR-506 and miR150 mimics, CD133 level increased by 20% and 16%,
respectively, compared to control groups (*p < 0.05).
In addition, CD133 levels increased by 12% and 14%
in miR-506 or miR-150 mimic transfected-MiaPaCa-2
leptin+ cells, respectively. However, palbociclib decreased
CD133 level by approximately 7% in these cells (*p <
0.05). CD24 expression was 70% in Panc-1 leptin+ cells
and this rate decreased by 10% with palbociclib (**p <
0.02). The increase in miR-506 and miR-150 expressions
downregulated the CD24 levels in Panc-1 cells by 40%
(****p < 0.0001). In addition, CD24 levels decreased to 16%
(*p < 0.05) when these cells were exposed to palbociclib.
CD24 level decreased by 22% and 30% with the increase of
miR-506 and miR-150 in leptin+ Panc-1 cells, respectively,
as compared to leptin+ Panc-1 cells. However, palbociclib
caused further increase of CD24 levels (****p < 0.0001.
Although both miR-506 and miR-150 reduced CD24
levels in leptin-/+ MiaPaCa-2 cells, palbociclib treatment
resulted in increased CD24 levels in each cell condition.
3.7. Mimic miR-150 significantly suppressed the
CSC profile of pancreatic cancer cells by palbociclib
cotreatment
It has been observed that tumor formations can be
suppressed by the increase in miR-506 and miR-150
expressions in leptin- and leptin+ cells, and they create

A.

Panc-1 Leptin +
miR-506
miR-150 Anti-miR-208

-

Panc-1
3 µM PD Control
C.

Mimic miR-506 Mimic miR-150 Anti-miR-208

-

MiaPaCa-2 Leptin +
miR-506
miR-150 Anti-miR-208

-

-

E.

Mimic miR-506 Mimic miR-150 Anti-miR-208

Panc-1 Leptin +
3 µM PD Control

MiaPaCa-2 Leptin +
3 µM PD Control

Panc-1
3 µM PD
Control

RENCÜZOĞULLARI and ARISAN / Turk J Biol

MiaPaCa-2
3 µM PD
Control

-

mimic miR-506

200
150

****

mimic miR-150
Anti-miR-208

F.

****

****

100

****

****

***

50
0

Control

3 M PD

353

Leptin -

Control

3 M PD
Leptin +

Average Spheroid Diameter (
m)

Panc-1

D.
Average Spheroid Diameter (
m)

B.
MiaPaCa-2
3 µM PD Control

-

mimic miR-506

MiaPaCa-2
200
150

****

mimic miR-150
Anti-miR-208
****

****

100

****

****

***

50
0

Control

3 M PD

Leptin -

Control

3 M PD

Leptin +

RENCÜZOĞULLARI and ARISAN / Turk J Biol

G.

CD24+ cells (%)

mimic miR-506

CD44+ cells (%)

Panc-1
Leptin+
Leptin+ 3 M PD

Control
3 M PD

50

**

**

-

****

mimic miR-506

**

Panc-1
Control
3 M PD
****

60

**

****

****

40
*

20

-

-

mimic miR-506

mimic miR-506

100

****
mimic miR-150

**** *

80

****

mimic miR-150

MiaPaCa-2
Leptin+
Control
Leptin+ 3 M PD
3 M PD
** *
** *
*

*

60
40
20
0

mimic miR-150
Leptin+
Leptin+ 3 M PD
****

Leptin+
Leptin+ 3 M PD

20

K.

**

0

40

mimic miR-150

100

80

Control
3 M PD

60

0

-

CD133+ cells (%)

CD133+ cells (%)

CD133
CD24

****

150

0

I.

****

-

L.
60

mimic miR-506

mimic miR-150

MiaPaCa-2
Control
Leptin+
Leptin+ 3 M PD
3 M PD

80
CD24+ cells (%)

CD44+ cells (%)

CD44

40
20

MiaPaCa-2

80

Leptin+
Leptin+ 3 M PD

Control
3 M PD

60

0

H.

J.

Panc-1

80

*

****

****

40
20
0

-

mimic miR-506

mimic miR-150

Figure 5. Modulation of miR-506, miR-150, and miR-208 led to significant reduction of tumor spheroid forms of palbociclibtreated cells. A-B. The effect of miRNA modulations on the colony forming potential of the leptin+ Panc-1 (A) and MiaPaCa-2
(B) cells following palbociclib (3 µM PD) treatment. C-F. The effect of miR-506, miR-150, and miR-208 expressions on anchorageindependent growth in the presence and absence of palbociclib in leptin+/- Panc-1 (C-D) and MiaPaCa-2 (E-F) cells were analyzed
by soft agar assay. It was visualized using a light microscope at the end of the 14-day incubation period. A graph was created by taking
the average of the diameters of 5 different tumorsphere structures. ***p < 0.001, ****p < 0.0001. G-L. The effect of palbociclib on the
expression levels of CD44, CD133, and CD24 were analyzed with flow cytometry following modulation of mir-506, miR-150, or miR208 in leptin+/- Panc-1 and MiaPaCa-2 cells. CD44 levels Panc-1 (G) and MiaPaCa-2 (J), CD133 levels Panc-1 (H) and MiaPaCa-2
(K) and CD24 levels Panc-1 (I) and MiaPaCa-2 (L). Data presented is mean ± SD of at least three separate experiments * p < 0.05,
**p < 0.02, **** p < 0.0001.

a synergistic response in inhibiting cell proliferation
with palbociclib. Therefore, after miR-506 and miR-150
transfection, total protein isolation was performed from
leptin-/+ cells in the presence and absence of palbociclib.
Then the expression levels of N-cadherin, β-catenin,
p-GSK3β (S9), Dvl-2, Wnt5a/b, Notch1, and CD44 were
determined in Panc-1 cells by western blotting (Figures 6A
and 6B). Thirty micrograms of total protein lysate was run
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and transferred in 10%–12% SDS-PAGE under the same
conditions and time. The western blot resulting images
were acquired in Panc-1 and Panc-1 leptin+ cells at the
same exposure times in order to make comparisons for the
same primers. Accordingly, N-cadherin expression was
decreased with palbociclib and more with miR-506 and
miR-150 mimic transfection. N-cadherin level was higher
in Leptin+ Panc-1 cells but decreased with palbociclib
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treatment. In particular, miR-150 mimic and palbociclib
provided a significant decrease in N-cadherin levels.
As expected, the β-catenin level was expressed higher
in Panc-1 leptin+ cells. Although this level could not be
decreased with palbociclib, increased -expression level of
miR-506 or miR-150 decreased β-catenin levels. In fact,
a significant reduction in β-catenin level was observed
with miR-150 mimic and palbociclib treatment. The level
of p-GSK3β decreased with increased expression of miR506 and miR-150 in Panc-1 cells. Thus, it was thought
that they might have increased the activation of GSK3β.
Inhibition of GSK3β in leptin+ cells were an expected
result, but treatment of palbociclib specifically with the
miR-150 mimic inhibited GSK3β phosphorylation. Dvl-2
is a signaling molecule that functions in the Wnt signaling
pathway highly expresses in pancreatic cancer cells. Dvl-2
level in Panc-1 cells did not change much with palbociclib
treatment, but there was a significant decrease in Dvl-2
level with miR-506 and miR-150 mimic and palbociclib
treatment. An increase in Dvl-2 level with miR-506 mimic
in Leptin+ Panc-1 cells was noted. Wnt5a/b expression was
decreased in leptin -/+ Panc-1 cells treated with palbociclib.
Although, an increase in miR-506 expression did not make
a difference in Wnt5a/b expression, an increase in a miR150 level decreased Wnt5a/b expression. Notch-1, as the
target molecule of leptin, was increased in Panc-1 leptin+
cells, but this increase was suppressed by palbociclib.
CD44 expression was high in leptin+ cells, confirming the
results of immunofluorescence and cell flow cytometry.
In particular, the CD44 level decreased due to miR-150
mimic transfection and palbociclib treatments.
The expression levels of p-Akt (Ser473), E-cadherin,
β-catenin, Vimentin, Dvl-2, Notch1 and Snail were
determined in leptin-/+ MiaPaCa-2 cells (Figures 6C
and 6D). Akt Ser473 phosphorylation is related to
the activation of Akt and was inhibited by palbociclib
treatment in MiaPaCa-2 cells. miR-506 and miR-150
mimic suppressed Akt phosphorylation. However, miR506 and miR-150 alone caused an increase in mimic
p-Akt, but palbociclib completely suppressed this increase
in leptin+ cells. E-cadherin levels were lower in Leptin+
MiaPaCa-2 cells when compared with leptin- cells.
Forced expression of miR-150 or miR-506 significantly
upregulated the E-cadherin levels and combination
with Palbociclib further increased the E-cadherin levels.
The level of β-catenin was decreased in MiaPaCa-2 cells
treated with palbociclib, but palbociclib did not make an
effective difference on β-catenin in leptin+ cells. mimic
miR-506 and miR-150 provided a significant reduction in
β-catenin expression. The expression levels of Vimentin,
Dvl-2, Notch and Snail were found to be expressed more
in leptin+ cells, and when miR-150 expression increased
their levels significantly decreased in both leptin- and
leptin+ MiaPaCa-2 cells. Both mimic miR-506 and

miR-150 synergistically reduced the expression levels of
mesenchymal markers by palbociclib treatment.
4. Discussion
Obesity is a risk factor for pancreatic cancer presenting the
increased plasma leptin level in and activating different
signaling targets such as matrix-metalloproteinase-13
signaling resulting in increased angiogenesis (Yeh et
al., 2009). In correlation with obesity, the modulated
leptin signaling was a factor for PC that promoted
cell proliferation by activating STAT3 and PI3K/Akt
signals. We suggested that leptin mediated increased
cell proliferation in PC drives aggressive phenotype of
tumorigenesis potential. It is noteworthy that Notch is a
contributing mechanism for colony formation mediated
by leptin-induced changes in Wnt/β-catenin signaling.
The induction of 3D forms of cells was apparent following
leptin treatment at 40 ng/mL to mimic serum leptin
concentration of obese patients (Buettner et al., 2006).
Similarly, in vitro treatment of recombinant leptin to
pancreatic cancer cells caused a significant increase in
p-Akt in Panc-02 and Panc-1 pancreatic cancer cells, but
MiaPaCa-2 cells did not activate p-Akt in response to
leptin regarded to the short and long forms of the leptin
receptor in cells (Mendonsa et al., 2015). It has been shown
that tumor formations are cell-dependent in Panc-1 and
MiaPaCa-2 xenograft models after leptin applications.
Leptin acts as an mTOR activator and triggers intracellular
protein and fat synthesis; however, our results are
compatible with the literature in that leptin increases
p-p70S6K and p-S6 activity in MiaPaCa-2 cells (Fazolini
et al., 2015; Rencuzogulları et al., 2021). Activation of
cell survival signals triggered by leptin was blocked by
palbociclib treatment in Panc-1 and MiaPaCa-2 cells
(Rencuzogullari et al., 2021). However, when each cell
was compared with its own control group, Akt/mTOR and
hedgehog and Wnt/β-catenin signal members were found
to be high despite the treatment of palbociclib to leptin+
cells. In addition, CD133 level increased in MiaPaCa-2
cells treated with leptin, but remained unchanged in Panc1 cells. CD133+ cells have active Wnt/β-catenin signaling
and are in the migration stage when the rate of CD133+
cells is 9% in pancreatic tumors (Gzil et al., 2019). In this
case, palbociclib and miRNA expressions targeting these
signals were modulated suppressed the activation of these
signaling pathways that provide cancer stem cell renewal
and proliferation.
The effects of palbociclib on cell viability, EMT process,
and stem cell markers by modulating miRNA expressions
in Panc-1, MiaPaCa-2, and Capan-2 cells are discussed for
each miRNA, respectively.
It has been determined that miR-506 is expressed at a
very low level in PC cells due to hypermethylation in the
miR-506 promoter region in PC cases (Li et al., 2016).
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Figure 6. Leptin-induced Notch signaling was significantly inhibited by palbociclib and miR-150 treatment in Panc-1 and MiaPaCa-2 cells. A-B. The expression levels of N-cadherin,
β-catenin, p-GSK3β (S9), Dvl-2, Wnt5a/b, Notch1, and CD44 were analyzed by western blotting in Leptin+/- Panc-1 cells that were transfected with miR-506 or miR-150 following
palbociclib treatment (3 µM PD). C-D. The expression levels of p-Akt (Ser473), E-cadherin, β-catenin, Vimentin, Dvl-2, Notch1, and Snail were analyzed by western blotting in
Leptin+/- MiaPaCa-2 cells that were transfected with miR-506 or miR-150 following palbociclib treatment (3 µM PD).
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Silencing of miR-506 due to hypermethylation has been
a factor that increases the pathogenesis and progression
of PC and causes poor prognosis. Palbociclib-mediated
upregulation of miR-506 in Panc-1 and MiaPaCa-2 cells
were similar to previous findings. In ovarian cancer,
miR-506 is defined as an EMT inhibitor that inhibits cell
migration and invasion; simultaneously, low level of miR506 expression in tumor tissues in clinical studies showed
a significant correlation with poor prognosis (Sun et al.,
2015). Similar results have been demonstrated in cervical,
breast, and gastric cancer, suggesting that miR-506 acts
as a tumor suppressor in these cancer types (Arora et al.,
2013; Wen et al., 2015). However, increased expression
of miR-506 in melanomas and colon cancer promoted
cell proliferation and acted as an oncogene as it caused
drug resistance (Tong et al., 2011). In addition, miR-506
is associated with various biological behaviors through
regulation of different target genes. Recent studies have
shown that miR-506 inhibits TGFβ-induced EMT by
targeting SNAI2 and suppressing vimentin and N-cadherin
expression in ovarian cancer (Tong et al., 2011). In
addition, miR-506 has been implicated in antiproliferative
functions by regulating CDK6 and Gli3 target genes.
These diverse observations of the roles of miR-506 are not
surprising because the function of miRNAs and their target
preferences can be highly dependent on the cellular and
disease context. In a study in PC cells, regain of miR-506
expression induced cell cycle arrest at the G1/S transition
and increased apoptosis and chemosensitivity. In the same
study, it was found that miR-506 targets Akt and suppresses
cell growth in vitro and in vivo (Li et al., 2016). In our study,
forced expression of miR-506 expression in each cell line
increased the effect of palbociclib to suppress EMT and
tumorigenesis, and reduce CD44 and CD24 expressions.
The additive effect of miR-506 to palbociclib treatment
was more effective in MiaPaCa-2 cells. The CSC profile
induced by leptin was inhibited by the increase of miR506 expression and increased the sensitivity of leptin-/+
Panc-1 and MiaPaCa-2 cells to palbociclib. Therefore, it
was thought that decreased miR-506 expression promoted
the tumorigenesis of pancreatic cancer, while induced
miR-506 expression increased the sensitivity of pancreatic
cancer cells to palbociclib.
miR-150 has been identified as an oncogene or a tumor
suppressor in various types of cancer (Chen et al., 2013;
Zhang et al., 2018). A decrease in miR-150 was seen in
most lymphohematopoietic tumors; however, increased
miR-150 has been reported in gastric cancer and colorectal
cancers metastases ( Wu et al., 2010; Li et al., 2018). The
opposing effects of miR-150 on malignant tumors can be
attributed to how its expression changes depending on cell
characteristics. To date, reports on the role of miR-150 in
the tumorigenesis of pancreatic cancers have been limited.
It has been determined that miR-150 is expressed at very
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low levels in pancreatic cancer tumor tissues (Srivastava
et al., 2011). According to the results obtained in clinical
studies from PC tissue samples, it was determined that
miR-150-positive individuals had a longer life expectancy
than miR-150-negative individuals. miR-150 expression
has been associated with tumor cell differentiation,
stage of disease, lymph node metastasis, neural invasion,
and distant metastasis in PC patients. c-Myc and Muc4,
which are highly expressed in PC tissues and are related
to aggression and metastasis, are among the target genes
of miR-150 (Srivastava et al., 2011). Accordingly, it is an
important outcome that c-Myc expression was reduced by
palbociclib in our study (Rencuzogulları et al., 2020). In
this study, the expression of β-catenin, which is among the
targets of miR-150, did not show any significant difference
when palbociclib was treated, especially in MiaPaCa-2 cells.
In addition, while the nuclear localization of β-catenin was
increased in MiaPaCa-2 cells treated with palbociclib; it
was decreased in Panc-1 cells (Rencuzogulları et al., 2020).
In relation to this, when miR-150 expression was examined
in MiaPaCa-2 cells, it was determined that palbociclib
caused a decrease in miR-150 expression. When miR-150
expression was increased in MiaPaCa-2 cells, β-catenin
expression was significantly decreased. Moreover, the
p-GSK3b (Ser9), Snail, Notch and Wnt5a/b level decreased
through increased expression of miR-150 and palbociclib
treatment in each cell line. It might be concluded that both
miR-150 mimic and palbociclib treatment suppressed
Wnt/b-catenin signaling mechanism. Tumorsphere
formation induced by leptin in Panc-1 and MiaPaCa-2
cells was also suppressed when miR-150 expression was
increased, increasing the sensitivity of cells to palbociclib
(Rencuzogullari et al., 2021). In summary, miR-150
induced different responses depending on the cell type in
the levels of tumor-initiating factors CD133 and CD24. In
conclusion, miR-150 and palbociclib induced a synergistic
response in inhibiting pancreatic cancer cell viability and
migration.
miR-208 is highly expressed in cancer tissues as an
oncomiR targeting E-cadherin which was increased
following palbociclib treatment when the immunoblot
results were compared (Rencuzogulları et al., 2020).
However, in the migration analysis, it was determined
that the migration rate of MiaPaCa-2 cells was higher in
direct proportion to the increase of miR-208 expression in
MiaPaCa-2 cells with palbociclib application, compared to
Panc-1 cells. Therefore, by inhibiting miR-208 expression,
palbociclib was found more effective in suppressing the
migration potential of MiaPaCa-2 cells.
As a result, palbociclib suppressed the CSC profile
triggered by leptin treatment, suppressing both
tumorsphere structures and target signaling pathways
of leptin, thereby breaking the resistance mechanism in
Panc-1 and MiaPaCa-2 cells. miRNA expressions altered
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by miR-506, miR-150 mimic and anti-miR-208 treatments
increased the sensitivity of Panc-1 and MiaPaCa-2
leptin-/+ cells to palbociclib. In accordance with the
literature, the downregulation of miR-506 and miR-150,
which are tumor suppressors, and upregulation of miR208, an oncomiR, are the results that predict that these
miRNAs can be used as a biomarker in PC cases with
further studies. The fact that PC consists of heterogeneous
cell groups is a parameter that limits the treatment process.
For this reason, it has been confirmed in our study that
monotherapies are insufficient in PC treatment, but the
use of an inhibitor together increases the success rate. In
the future, in vivo studies on developing miRNA therapies
with palbociclib are planned. Two of the main areas of
focus in the developing of miRNA therapeutics are to
increase the in vivo stability of therapeutic RNA molecules
and design optimal delivery systems for disease-specific
release with minimal toxicity.
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Figure S1. Effect of palbociclib on cell cycle phases in Panc-1 and MiaPaCa-2 cells transfected with miR-506, miR-150 mimic and anti-miR-208. Cells stained with PI were
analyzed by reading 104 cells in flow cytometry. Data represented by histogram analysis are the mean ± Std.Dev. of two separate experiments. * p<0.05, **** p <0.0001
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